Switch theme
Sign up to access all valuation multiples
CytomX Therapeutics Inc a clinical-stage, oncology-focused biopharmaceutical company developing novel, masked, conditionally activated biologics designed to be localized to the tumor microenvironment. It is engaged in developing antibody therapeutics based on probody technology platforms. The company's probody technology platform creates proprietary cancer immunotherapies against clinically-validated targets and develops cancer therapeutics. Probody therapeutics are designed to take advantage of conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues.
2010
121
LTM Revenue $122M
LTM EBITDA $17.3M
$343M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
CytomX Therapeutics has a last 12-month revenue (LTM) of $122M and a last 12-month EBITDA of $17.3M.
In the most recent fiscal year, CytomX Therapeutics achieved revenue of $138M and an EBITDA of $26.8M.
CytomX Therapeutics expects next 12-month revenue of XXX and NTM EBITDA of XXX
See CytomX Therapeutics valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $122M | XXX | $138M | XXX | XXX | XXX |
| Gross Profit | $122M | XXX | n/a | XXX | XXX | XXX |
| Gross Margin | 100% | XXX | n/a | XXX | XXX | XXX |
| EBITDA | $17.3M | XXX | $26.8M | XXX | XXX | XXX |
| EBITDA Margin | 14% | XXX | 19% | XXX | XXX | XXX |
| EBIT | $9.9M | XXX | $25.0M | XXX | XXX | XXX |
| EBIT Margin | 8% | XXX | 18% | XXX | XXX | XXX |
| Net Profit | $15.7M | XXX | $31.9M | XXX | XXX | XXX |
| Net Margin | 13% | XXX | 23% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, CytomX Therapeutics's stock price is $3.
CytomX Therapeutics has current market cap of $415M, and EV of $343M.
See CytomX Therapeutics trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $343M | $415M | XXX | XXX | XXX | XXX | $0.18 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, CytomX Therapeutics has market cap of $415M and EV of $343M.
CytomX Therapeutics's trades at 2.5x EV/Revenue multiple, and 12.8x EV/EBITDA.
Equity research analysts estimate CytomX Therapeutics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
CytomX Therapeutics has a P/E ratio of 26.5x.
See valuation multiples for CytomX Therapeutics and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $415M | XXX | $415M | XXX | XXX | XXX |
| EV (current) | $343M | XXX | $343M | XXX | XXX | XXX |
| EV/Revenue | 2.8x | XXX | 2.5x | XXX | XXX | XXX |
| EV/EBITDA | 19.9x | XXX | 12.8x | XXX | XXX | XXX |
| EV/EBIT | 34.6x | XXX | 13.7x | XXX | XXX | XXX |
| EV/Gross Profit | 2.8x | XXX | n/a | XXX | XXX | XXX |
| P/E | 26.5x | XXX | 13.0x | XXX | XXX | XXX |
| EV/FCF | -5.8x | XXX | -4.0x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialCytomX Therapeutics's last 12 month revenue growth is -30%
CytomX Therapeutics's revenue per employee in the last FY averaged $1.1M, while opex per employee averaged $0.9M for the same period.
CytomX Therapeutics's rule of 40 is -35% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
CytomX Therapeutics's rule of X is -62% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for CytomX Therapeutics and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | -30% | XXX | -31% | XXX | XXX | XXX |
| EBITDA Margin | 14% | XXX | 19% | XXX | XXX | XXX |
| EBITDA Growth | -177% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | -35% | XXX | -11% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | -62% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $1.1M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.9M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 60% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 82% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
CytomX Therapeutics acquired XXX companies to date.
Last acquisition by CytomX Therapeutics was XXXXXXXX, XXXXX XXXXX XXXXXX . CytomX Therapeutics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was CytomX Therapeutics founded? | CytomX Therapeutics was founded in 2010. |
| Where is CytomX Therapeutics headquartered? | CytomX Therapeutics is headquartered in United States of America. |
| How many employees does CytomX Therapeutics have? | As of today, CytomX Therapeutics has 121 employees. |
| Who is the CEO of CytomX Therapeutics? | CytomX Therapeutics's CEO is Dr. Sean A. McCarthy, D.Phil.. |
| Is CytomX Therapeutics publicy listed? | Yes, CytomX Therapeutics is a public company listed on NAS. |
| What is the stock symbol of CytomX Therapeutics? | CytomX Therapeutics trades under CTMX ticker. |
| When did CytomX Therapeutics go public? | CytomX Therapeutics went public in 2015. |
| Who are competitors of CytomX Therapeutics? | Similar companies to CytomX Therapeutics include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of CytomX Therapeutics? | CytomX Therapeutics's current market cap is $415M |
| What is the current revenue of CytomX Therapeutics? | CytomX Therapeutics's last 12 months revenue is $122M. |
| What is the current revenue growth of CytomX Therapeutics? | CytomX Therapeutics revenue growth (NTM/LTM) is -30%. |
| What is the current EV/Revenue multiple of CytomX Therapeutics? | Current revenue multiple of CytomX Therapeutics is 2.8x. |
| Is CytomX Therapeutics profitable? | Yes, CytomX Therapeutics is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of CytomX Therapeutics? | CytomX Therapeutics's last 12 months EBITDA is $17.3M. |
| What is CytomX Therapeutics's EBITDA margin? | CytomX Therapeutics's last 12 months EBITDA margin is 14%. |
| What is the current EV/EBITDA multiple of CytomX Therapeutics? | Current EBITDA multiple of CytomX Therapeutics is 19.9x. |
| What is the current FCF of CytomX Therapeutics? | CytomX Therapeutics's last 12 months FCF is -$59.5M. |
| What is CytomX Therapeutics's FCF margin? | CytomX Therapeutics's last 12 months FCF margin is -49%. |
| What is the current EV/FCF multiple of CytomX Therapeutics? | Current FCF multiple of CytomX Therapeutics is -5.8x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
